X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CY6463
Therapeutic Area: Neurology Product Name: CY6463
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Cyclerion Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
Details:
IXICO has been selected by Cyclerion Therapeutics, Inc., a new client, to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
